Patents by Inventor Chenchao Xu

Chenchao Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LONG-ACTING AND LOW-TOXIC RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY AND PRODUCTION METHOD THEREFOR
    Publication number: 20210079081
    Abstract: The present invention relates to a full length humanized monoclonal antibody that can specifically bind to VEGF. The antibody can inhibit binding of VEGF to VEGFR-1 and VEGFR-2, thereby inhibiting signaling of VEGF. The antibody has a strong affinity for VEGF, has a long half-life, and is highly safe after vitreous injection. The antibody of the invention may be effective in treating diseases associated with VEGF overexpression, particularly diseases associated with abnormal angiogenesis caused by VEGF overexpression.
    Type: Application
    Filed: January 4, 2019
    Publication date: March 18, 2021
    Applicant: BIO-THERA SOLUTIONS, LTD.
    Inventors: Xiaoyun Wu, Chenchao Xu, Zhigang Wang, Shengfeng Li
  • Bispecific antibodies which bind EGFR and VEGF
    Patent number: 9567403
    Abstract: Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: February 14, 2017
    Assignee: Bio-Thera Solutions, Ltd.
    Inventors: Xiaoyun Wu, Shengfeng Li, Chenchao Xu
  • BISPECIFIC ANTIBODIES
    Publication number: 20150044216
    Abstract: Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 12, 2015
    Inventors: Xiaoyun Wu, Shengfeng Li, Chenchao Xu